- Home
- CPT vs EXEL Comparison
CPT vs EXEL Comparison
Compare CPT & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPT
- EXEL
- Stock Information
- Founded
- CPT 1993
- EXEL 1994
- Country
- CPT United States
- EXEL United States
- Employees
- CPT N/A
- EXEL N/A
- Industry
- CPT Real Estate Investment Trusts
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPT Real Estate
- EXEL Health Care
- Exchange
- CPT Nasdaq
- EXEL Nasdaq
- Market Cap
- CPT 10.9B
- EXEL 10.4B
- IPO Year
- CPT 1993
- EXEL 2000
- Fundamental
- Price
- CPT $100.03
- EXEL $40.61
- Analyst Decision
- CPT Buy
- EXEL Buy
- Analyst Count
- CPT 18
- EXEL 24
- Target Price
- CPT $121.60
- EXEL $44.73
- AVG Volume (30 Days)
- CPT 1.3M
- EXEL 3.2M
- Earning Date
- CPT 11-06-2025
- EXEL 11-04-2025
- Dividend Yield
- CPT 4.23%
- EXEL N/A
- EPS Growth
- CPT N/A
- EXEL 53.55
- EPS
- CPT 1.43
- EXEL 2.38
- Revenue
- CPT $1,570,124,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- CPT $2.74
- EXEL $9.14
- Revenue Next Year
- CPT $2.57
- EXEL $12.51
- P/E Ratio
- CPT $69.34
- EXEL $17.17
- Revenue Growth
- CPT 0.75
- EXEL 9.93
- 52 Week Low
- CPT $97.17
- EXEL $31.90
- 52 Week High
- CPT $127.65
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- CPT 40.39
- EXEL 57.90
- Support Level
- CPT $97.88
- EXEL $36.00
- Resistance Level
- CPT $102.16
- EXEL $41.55
- Average True Range (ATR)
- CPT 1.95
- EXEL 1.51
- MACD
- CPT 0.01
- EXEL 0.23
- Stochastic Oscillator
- CPT 32.56
- EXEL 88.00
About CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.